Merus N V (MRUS) Return on Investment ROI from the third quarter of 2025 to third quarter of 2024 and for the year 2025, average high and low, overall ranking from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Merus N v   (NASDAQ: MRUS)


Merus N V's ROI from its third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Merus N V's ROI in the third quarter of 2025?
Merus N V recorded a cumulative net loss of $-381 million during 12 months ending in the third quarter of 2025, resulting in a negative return on investment (ROI) of -50.05%.

Within the Healthcare sector 478 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2025 from 3326 to 3398.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Investment Change TTM 27.71 % 46.13 % 90 % 95.4 % 84.87 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 817 889 642 698 765
Return On Investment (TTM) -50.05 % -51.52 % -38.05 % -31.98 % -41.02 %
MRUS's Overall Ranking # 3398 # 3326 # 2718 # 2221 # 3041
Seq. Investment Change TTM 1.76 % 2.65 % 8.25 % 12.94 % 16.44 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -381 -386 -277 -215 -245

MRUS Company Profile >> Back to MRUS Roi Comparisons >> See Annual MRUS Return On Investment



Return On Investment MRUS's Ranking
Within: No.
Industry # 201
Sector # 479
Overall # 3398

Return On Investment Statistics
High Average Low
-15.29 %
-37.45 %
-58.98 %
(Jun 30 2022)   (Jun 30 2023)



  News about Merus N v Return on Investment ROI

Merus Doses First Patient in Phase 3 Trials for Petosemtamab in Oncology Indications

September 30, 2024

Merus N.V. a clinical-stage oncology company specializing in the development of innovative multispecific antibodies, has announced significant advancements in its clinical trials for petosemtamab, a novel therapy targeting epidermal growth factor receptor (EGFR) and LGR5. The company has recently initiated two pivotal clinical trials, expanding its exploration of petosemtamab s efficacy in treating different malignancies, specifically recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) and metastatic colorectal cancer (mCRC).On September 30, 2024, Merus reported that the first patient has been dosed in the Phase 3 trial known as LiGeR-HN1. This trial is designed to evaluate the safety and efficacy of petosemtamab when used in combination with pembrolizumab, an established checkpoint inhibitor, in patients with PD-L1 positive r/m HNSCC. The LiGeR-HN1 trial aims to compare the combination therapy against pembrolizumab monotherapy as the first-line treatment approach. The inclusion of petosemtamab, classified as a Biclonics dual-targeting antibody, is expected to enhance the therapeutic impact in this patient population.

Merus N.V. Pursues $300 Million Public Offering to Fuel Innovative Cancer Treatment Development

May 28, 2024

Merus N.V. Seeks $300 Million Through Proposed Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 - Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in the development of innovative, full-length multispecific antibodies, has announced its intention to launch a proposed underwritten public offering of $300,000,000 worth of its common shares. The offering, subject to market conditions and other closing conditions, is expected to be made in the near future. Merus plans to use the proceeds from the offering for general corporate purposes, including furthering its clinical development efforts and enhancing its commercial infrastructure.
Merus is a company focused on oncology treatments, specifically the development of Biclonics and Triclonics, which are full-length multispecific antibodies. These antibodies are designed to simultaneously bind to multiple cancer targets, enhancing their potential therapeutic effects. By leveraging the unique properties of Biclonics and Triclonics, Merus aims to develop more effective and targeted treatment options for patients with various types of cancer.





Financial Statements
Merus N V's III. Quarter Investments $ 817 Millions MRUS's Balance sheet
Merus N V's III. Quarter Income $ -96 Millions Quarterly MRUS's Income Statement
MRUS's Income by Division See MRUS's Income by Division


MRUS Annual Return On Investment (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Investments in Millions 698 389 301 386 186
Y / Y Investment Growth 79.26 % 29.38 % -21.98 % 107.86 % -18.57 %
Net Income in Millions -215 -155 -131 -67 -86
Y / Y Net Income Growth - - - - -
Annual Return On Investment -30.85 % -39.79 % -43.59 % -17.32 % -46.08 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
MRUS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for MRUS's Competitors
Subscribers only: Roi for Merus N V's Suppliers
Subscribers only: Return On Investment for MRUS's Customers

Other Ratios
MRUS's Roa MRUS's Inventory Turnover Ratio MRUS's Growth Rates MRUS's Dividend Statistics
MRUS's Profitability Ratios MRUS's Asset Turnover Ratio MRUS's Dividend Growth
MRUS's Roe MRUS's Valuation Ratios MRUS's Financial Strength Ratios MRUS's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2025, within Healthcare Sector ROI

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.